JP2018514511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514511A5 JP2018514511A5 JP2017550122A JP2017550122A JP2018514511A5 JP 2018514511 A5 JP2018514511 A5 JP 2018514511A5 JP 2017550122 A JP2017550122 A JP 2017550122A JP 2017550122 A JP2017550122 A JP 2017550122A JP 2018514511 A5 JP2018514511 A5 JP 2018514511A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oil
- composition according
- carcinoma
- breast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 36
- -1 vitamin D compound Chemical class 0.000 claims 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 7
- 239000003921 oil Substances 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 235000019198 oils Nutrition 0.000 claims 6
- 229930003316 Vitamin D Natural products 0.000 claims 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims 5
- 229930195729 fatty acid Natural products 0.000 claims 5
- 239000000194 fatty acid Substances 0.000 claims 5
- 150000004665 fatty acids Chemical class 0.000 claims 5
- 235000019166 vitamin D Nutrition 0.000 claims 5
- 239000011710 vitamin D Substances 0.000 claims 5
- 229940046008 vitamin d Drugs 0.000 claims 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 4
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 229940119564 Selective estrogen receptor downregulator Drugs 0.000 claims 3
- 239000003886 aromatase inhibitor Substances 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000000839 emulsion Substances 0.000 claims 3
- 229960002061 ergocalciferol Drugs 0.000 claims 3
- 229960002258 fulvestrant Drugs 0.000 claims 3
- 239000007764 o/w emulsion Substances 0.000 claims 3
- 229960001603 tamoxifen Drugs 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 239000011653 vitamin D2 Substances 0.000 claims 3
- BURHGPHDEVGCEZ-KJGLQBJMSA-N (e)-3-[4-[(e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-enyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(F)C=C(Cl)C=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C1=CC=C(\C=C\C(O)=O)C=C1 BURHGPHDEVGCEZ-KJGLQBJMSA-N 0.000 claims 2
- JICOGKJOQXTAIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol Chemical compound C=1C=C(OCCN2CCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 JICOGKJOQXTAIP-UHFFFAOYSA-N 0.000 claims 2
- MHJBZVSGOZTKRH-IZHYLOQSSA-N 4-Hydroxy-N-desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=C(O)C=C1 MHJBZVSGOZTKRH-IZHYLOQSSA-N 0.000 claims 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims 2
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 claims 2
- NYDCDZSEEAUOHN-IZHYLOQSSA-N N-Desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=CC=C1 NYDCDZSEEAUOHN-IZHYLOQSSA-N 0.000 claims 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 2
- 229920002125 Sokalan® Polymers 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229960002932 anastrozole Drugs 0.000 claims 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 claims 2
- 229950005529 arzoxifene Drugs 0.000 claims 2
- 229960000817 bazedoxifene Drugs 0.000 claims 2
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 claims 2
- 208000030270 breast disease Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims 2
- 229960003608 clomifene Drugs 0.000 claims 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 2
- 229950004203 droloxifene Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960000255 exemestane Drugs 0.000 claims 2
- 239000003349 gelling agent Substances 0.000 claims 2
- 229950002248 idoxifene Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960002367 lasofoxifene Drugs 0.000 claims 2
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 claims 2
- 229960003881 letrozole Drugs 0.000 claims 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 229960004622 raloxifene Drugs 0.000 claims 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 2
- 229960005026 toremifene Drugs 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims 2
- 235000001892 vitamin D2 Nutrition 0.000 claims 2
- 239000011647 vitamin D3 Chemical class 0.000 claims 2
- 235000005282 vitamin D3 Nutrition 0.000 claims 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 2
- 229940021056 vitamin d3 Drugs 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- HPSWUFMMLKGKDS-DNKOKRCQSA-N (2e,4e,6e,8e,10e,12e)-tetracosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O HPSWUFMMLKGKDS-DNKOKRCQSA-N 0.000 claims 1
- KXVFBCSUGDNXQF-DZDBOGACSA-N (2z,4z,6z,8z,10z)-tetracosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C=C/C(O)=O KXVFBCSUGDNXQF-DZDBOGACSA-N 0.000 claims 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims 1
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 claims 1
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 claims 1
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 claims 1
- KJKIIUAXZGLUND-ICCVIKJNSA-N 25-hydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C KJKIIUAXZGLUND-ICCVIKJNSA-N 0.000 claims 1
- 241000321096 Adenoides Species 0.000 claims 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 102000016736 Cyclin Human genes 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 1
- 208000000265 Lobular Carcinoma Diseases 0.000 claims 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 210000002534 adenoid Anatomy 0.000 claims 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940087168 alpha tocopherol Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 201000003714 breast lobular carcinoma Diseases 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 229920006184 cellulose methylcellulose Polymers 0.000 claims 1
- 229960002798 cetrimide Drugs 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 125000001033 ether group Chemical group 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 1
- 208000030776 invasive breast carcinoma Diseases 0.000 claims 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims 1
- XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 claims 1
- 229950002728 levormeloxifene Drugs 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 208000035803 proliferative type breast fibrocystic change Diseases 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 235000010388 propyl gallate Nutrition 0.000 claims 1
- 229940075579 propyl gallate Drugs 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 201000007423 tubular adenocarcinoma Diseases 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562147536P | 2015-04-14 | 2015-04-14 | |
| US62/147,536 | 2015-04-14 | ||
| PCT/US2016/026170 WO2016168021A1 (en) | 2015-04-14 | 2016-04-06 | Compositions and methods of treatment of breast disorders and estrogen-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018514511A JP2018514511A (ja) | 2018-06-07 |
| JP2018514511A5 true JP2018514511A5 (cg-RX-API-DMAC7.html) | 2019-04-11 |
Family
ID=57127000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550122A Pending JP2018514511A (ja) | 2015-04-14 | 2016-04-06 | 乳房障害とエストロゲン関連障害の処置のための組成物と方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180049999A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3283061A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018514511A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107708678A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016247674A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2981301A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016168021A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180169034A1 (en) * | 2015-06-14 | 2018-06-21 | Trs Ii, Llc | Transdermal delivery formulation |
| CA2992282A1 (en) * | 2015-07-14 | 2017-01-19 | Atossa Genetics Inc. | Transpapillary methods and compositions for treating breast disorders |
| CN110099680B (zh) | 2016-10-11 | 2021-02-05 | 杜克大学 | Er+乳腺癌的拉索昔芬治疗 |
| CN111212635A (zh) * | 2017-09-11 | 2020-05-29 | 阿托莎医疗公司 | 局部用组合物 |
| EP3681491A4 (en) | 2017-09-11 | 2021-06-30 | Atossa Therapeutics, Inc. | PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES |
| TW201919594A (zh) * | 2017-09-11 | 2019-06-01 | 美商艾陶莎基因有限公司 | 局部用組合物及治療方法 |
| CA3094072A1 (en) * | 2018-03-15 | 2019-09-19 | Atossa Therapeutics, Inc. | In situ methods of inducing of immune response |
| CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| WO2019232485A1 (en) * | 2018-05-31 | 2019-12-05 | Nvigen, Inc. | Accurate blood test to predict cancer incidence, recurrence, guide and monitor treatment intervention |
| US12390435B2 (en) | 2018-11-14 | 2025-08-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Electrophiles and electrophile pro-drugs as RAD51 inhibitors |
| IT201900003843A1 (it) * | 2019-03-15 | 2020-09-15 | Lo Li Pharma Srl | Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG) |
| EP3980006A2 (en) * | 2019-06-07 | 2022-04-13 | Diomics Corporation | Topical time release delivery using layered biopolymer |
| WO2021003433A1 (en) * | 2019-07-03 | 2021-01-07 | Atossa Therapeutics, Inc. | Sustained release compositions of endoxifen |
| BR112022001165A2 (pt) * | 2019-07-23 | 2022-05-17 | Scherer Technologies Llc R P | Formulações de cápsula de casca macia e métodos de preparação e uso das mesmas |
| US11915811B2 (en) * | 2019-09-03 | 2024-02-27 | Kaival Labs, Inc. | System and method for determining an appropriate dose of a product |
| KR20220154196A (ko) * | 2020-03-18 | 2022-11-21 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 연질겔 캡슐 |
| WO2021231904A1 (en) * | 2020-05-14 | 2021-11-18 | Diomics Corporation | Detection and indication of covid-19, other viruses and pathogens and vaccine associated efficacy |
| CN111420046B (zh) * | 2020-05-27 | 2021-01-12 | 四川省畜牧科学研究院 | 一种动物疫苗佐剂及其制备方法 |
| WO2022187511A1 (en) * | 2021-03-03 | 2022-09-09 | Veramorph Llc | Dissociating polymer matrix compositions of fulvestrant and methods of their making and use |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| KR102864596B1 (ko) * | 2022-04-25 | 2025-09-26 | 유엠에스엔지니어링 주식회사 | 오메가 3 심리스 연질캡슐 제조방법 |
| WO2025174794A1 (en) * | 2024-02-12 | 2025-08-21 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149851A (en) * | 1990-10-25 | 1992-09-22 | The United States Of America As Represented By The Secretary Of Commerce | Process for preparing triglycerides containing polyunsaturated fatty acid moieties |
| US5613958A (en) * | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
| DE19738643C2 (de) * | 1997-09-04 | 2001-10-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Scopolaminbase und Verfahren zu seiner Herstellung |
| WO2001001962A1 (en) * | 1999-07-05 | 2001-01-11 | Idea Ag. | A method for the improvement of transport across adaptable semi-permeable barriers |
| DE20013336U1 (de) * | 2000-08-02 | 2001-02-15 | Bieger, Wilfried P., Priv.-Doz. Dr.med.habil., 80335 München | Mund- und Zahnpflegegel |
| NZ552316A (en) * | 2006-12-22 | 2009-10-30 | Fonterra Co Operative Group | Dairy product and process |
| WO2008113177A1 (en) * | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| US20090068190A1 (en) * | 2007-08-29 | 2009-03-12 | Drugtech Corporation | Anti-proliferative combinations |
| WO2014093313A1 (en) * | 2012-12-10 | 2014-06-19 | Jingxuan Kang | Compositions and methods for integrated metabolic interventions |
| US8728546B1 (en) * | 2013-03-15 | 2014-05-20 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer, cardiovascular diseases and inflammation |
| MX370055B (es) * | 2013-04-22 | 2019-11-29 | Smartfish As | Uso de una composición que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cáncer. |
| CN103734512A (zh) * | 2013-12-20 | 2014-04-23 | 晓健科技(大连)有限公司 | 一种宠物猫补钙营养膏 |
| CA2992282A1 (en) * | 2015-07-14 | 2017-01-19 | Atossa Genetics Inc. | Transpapillary methods and compositions for treating breast disorders |
-
2016
- 2016-04-06 EP EP16780471.5A patent/EP3283061A4/en not_active Withdrawn
- 2016-04-06 AU AU2016247674A patent/AU2016247674A1/en not_active Abandoned
- 2016-04-06 CN CN201680034873.1A patent/CN107708678A/zh active Pending
- 2016-04-06 WO PCT/US2016/026170 patent/WO2016168021A1/en not_active Ceased
- 2016-04-06 US US15/561,249 patent/US20180049999A1/en not_active Abandoned
- 2016-04-06 JP JP2017550122A patent/JP2018514511A/ja active Pending
- 2016-04-06 CA CA2981301A patent/CA2981301A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108135177B (zh) | 用于治疗癌症的方法 | |
| US20180049999A1 (en) | Compositions and methods of treatment of breast disorders and estrogen-related disorders | |
| JP2023508325A5 (cg-RX-API-DMAC7.html) | ||
| CN111670036A (zh) | 包含托法替尼的局部调配物 | |
| CA2932106A1 (en) | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer | |
| SG175823A1 (en) | Use of pufas for treating skin inflammation | |
| ES2877712T3 (es) | Terapias combinadas para su uso en el tratamiento del cáncer de mama | |
| JP2021020955A (ja) | 経皮製剤 | |
| US8680054B2 (en) | Suspension type topical formulations comprising cyclic depsipeptide | |
| ES2865254T3 (es) | Composiciones para el tratamiento de la vaginitis atrófica, dispareunia perimenopáusica y posmenopaúsica y/o mujeres ooforectomizadas y métodos de tratamiento con las mismas | |
| JP2018520182A5 (cg-RX-API-DMAC7.html) | ||
| CN106163280A (zh) | 小檗碱制剂及其用途 | |
| CN103347498B (zh) | 组蛋白脱乙酰酶抑制剂药物配方 | |
| TWI510243B (zh) | 用於治療膀胱癌的組成物及方法 | |
| CN109640958B (zh) | 包含选择性雌激素受体调节剂(serm)的阴道递送系统及其用途 | |
| TW201919608A (zh) | 局部用組合物 | |
| JP2021508334A (ja) | 男性型禿頭症を含む皮膚障害を処置するための局所製剤 | |
| KR20080041695A (ko) | O-데스메틸 벤라팍신 (odv) 또는 이의 염을 함유하는국소 제형 | |
| TW201919594A (zh) | 局部用組合物及治療方法 | |
| JP2014024768A (ja) | 皮膚外用剤組成物 | |
| MX2011001382A (es) | Tratamiento de atrofia vaginal en mujeres con riesgo de patologia tumoral. | |
| AU2017285258A1 (en) | Compositions comprising timolol and an anti-inflammatory agent | |
| JP2023516754A (ja) | 環状デプシペプチドの局所医薬製剤 | |
| JP2025528197A (ja) | 真菌感染治療のための抗真菌剤の局所送達 | |
| JP2016196454A (ja) | 涙腺ドラッグデリバリーシステム |